Last reviewed · How we verify
Antihyperglycemic Medication
This drug reduces blood glucose by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidney, allowing excess glucose to be excreted in urine.
This drug reduces blood glucose by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidney, allowing excess glucose to be excreted in urine. Used for Type 2 diabetes mellitus, Heart failure with reduced ejection fraction, Chronic kidney disease.
At a glance
| Generic name | Antihyperglycemic Medication |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 (sodium-glucose cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
SGLT2 inhibitors work by blocking the reabsorption of filtered glucose in the proximal tubule of the nephron, thereby increasing urinary glucose excretion and lowering blood glucose levels. This mechanism is independent of insulin secretion or action, making it effective across different stages of type 2 diabetes. The class also provides cardiovascular and renal protective benefits beyond glucose lowering.
Approved indications
- Type 2 diabetes mellitus
- Heart failure with reduced ejection fraction
- Chronic kidney disease
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Polyuria
- Diabetic ketoacidosis
- Volume depletion
Key clinical trials
- Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors
- SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism (PHASE2)
- Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT) (NA)
- The Use of Advanced Imaging in HFpEF
- Safety and Effectiveness of Overripe Banana Powder Added to Diabetic Formulas in Type 2 Diabetes (NA)
- Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3
- A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes (PHASE3)
- Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antihyperglycemic Medication CI brief — competitive landscape report
- Antihyperglycemic Medication updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI